SciSparc Ltd. (SPRC) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SciSparc Ltd., a pharmaceutical company specializing in central nervous system disorders, has revealed a promising collaboration with Clearmind Medicine Inc., focusing on a ketamine-based therapy combination for mental health, addictions, and weight loss. Their joint research has led to the filing of thirteen patents for treatments combining SciSparc’s PEA compound with Clearmind’s psychedelic molecule MEAI. This novel approach aims to reduce dosage requirements and minimize side effects while maintaining therapeutic effectiveness.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.